BEATS= 1
CYCLELENGTH=  600
MYOCYTE= NORMAL FEMALE $ MODIFIED or NORMAL + MALE OR FEMALE (AT 600bcl) or NORMAL PIG $ FDA model optimization
ON_DRUGS= NO
$------------------------
CONDUCTANCES
$!! Male Phenotype. Female Phenotype is commented below!!
INAME= HUMAN
$---1 conductance ito channel (GIto)
$1.0 1.0 0.6
0.64 1.0 0.26  
$---2 conductance slow potassium channel (GKs) ****
$1.87 1.87 1.04
0.83 1.87 0.87 
$---3 conductance potassium channel (GK1)  ****
$1.698 1.698 0.98
0.86 1.698 0.74 
$---4 conductance rapid potassium channel (GKr) ****
$1.013 1.013 1.09
0.79 1.013 0.875
$---5 conductance sodium channel (GNa)  ****
1.0 1.0 1.0
$---6 conductance late sodium channel (GNaL)  ****
2.661 2.661 2.661
$---7 conductance sodium calcium exchanger (GNaCa) ****
1.0 1.0 1.0
$---8 background potassium background current conductance (gKb) ****
1.0 1.0 1.0
$---9 L-type calcium current permeability (pCa equiv to gCaL)  ****
$1.007 1.007 0.88
1.6 1.007 1.6
$---10 sodium potassium pump current permeability (pNaK)
$1.0 1.0 0.94
0.79 1.0 0.7
$---11 Calmodulin
$1.0 1.0 1.07
1.21 1.0 1.41
$---12 Serca Pump (Jup)
$1.0 1.0 1.42
1.15 1.0 1.97

$---13 Na0 Ca0 K0 concentrations percentage of change of concentration
1.0 1.0 1.0

END_CONDUCTANCES
$------------------------
 DOSIS
  INAME= AMIODARONE
$--- Dosis to affect L-type Calcium current (ICaL_dosis)
   0.0
$--- IC50 of L-type Calcium current (ICAL_IC50)
   270.0       
$--- Dosis to affect the Rapid Potassium Current (KR_DOSIS)
   0.0
$--- IC50 of Rapid Potasium Current (IKR_IC50)
   30.0  
$--- Dosis to affect the Sodium Channel (NA_DOSIS)
   0.0  
$--- IC50 of Sodium Channel (INA_IC50)
   4800.0 
$--- Dosis to affect the ITO Channel (ITO_DOSIS)
   0.0  
$--- IC50 of ITO Channel (ITO_IC50)
   4800.0 
 END_DOSIS
